- Supplier site
- Group of sites (click to zoom)
Scientist.com supplier network (site locations)
Research supplier
Clovis Oncology
Clovis Oncology is listed as a small business research supplier in the Scientist.com network, with 1 site in 1 country and 1 service area.
Sign in to Scientist.com to open this supplier in your organization's marketplace.
Search companies, drugs, suppliers and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Services
What this research supplier says it provides, as listed in the Scientist.com network.
Type of company: Small business
Biomarkers
- Solid Tumor CDx Design and validate companion diagnostics for solid tumors that help select the most appropriate patients, identify patients at increased risk, or monitor treatment effectiveness.
Service areas:
Where it operates
Sites by country, with the cities in each.
-
United States 1 site
About this supplier
In the supplier's own words, as listed in the Scientist.com network.
We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them. We have three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II clinical trials for the treatment...
Show the full description
We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.
We have three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. We maintain global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.
In addition, we are in the discovery phase for a compound to treat patients with gastrointestinal stromal tumors, or GIST, whose cancer is resistant to current therapies.
- Website
- www.clovisoncology.com
Work with Clovis Oncology on Scientist.com
For prices, more details, or to contact Clovis Oncology, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.